2021-05-04 07:26:07
Rockville, Maryland, May 4, 2021 – The Institute for Advanced Clinical Trials for Children (I-ACT for Children) is pleased to announce the appointment of Alexandre LeBeaut, MD as its new Chief Executive Officer, reporting to the Institute’s Board of Directors. Aligned with I-ACT for Children’s mission, Dr. LeBeaut (“Alex”) will have responsibility for both the…
2021-04-19 07:00:42
I-ACT for Children is pleased to announce the appointment of Cynthia Jackson, DO, FAAP as Chief Operating Officer, reporting to the Interim Chief Executive Officer. Dr. Jackson will have responsibility for the Institute’s site network, project management/clinical operations and overall business operations. Dr. Jackson is a pediatrician with a distinguished career in clinical trials services…
2021-04-14 16:41:13
We are pleased to post our webinar featuring a discussion of research compliance, understanding the value of prevention, and implementing preventive measures to help avoid research compliance issues. The webinar recording and associated slide deck provide useful information and tools to aid in developing preventive measures and help mitigate risks at your institution.
2021-04-14 16:39:58
We are pleased to post our fair market value webinar, which provides a clear explanation of the meaning of “fair market value,” and a discussion of the associated challenges for budgets based on these values. Also provided is an explanation of the role vendors and sponsors play in determining fair market value. The webinar recording…
2021-04-14 16:38:22
We are pleased to post our coverage analysis webinar. Not only does it provide a better understanding of what coverage analysis is and the importance of performing one, the webinar recording provides useful guidance on where to begin, what to consider when performing coverage analysis, and when to do it.
2021-04-05 06:30:33
The Institute for Advanced Clinical Trials for Children welcomes David Mc Neeley, MD, MPHTM as SVP Clinical Development, Pediatrics reporting to Dr. Gary Noel, I-ACT for Children’s Chief Medical Officer. Dr. Mc Neeley most recently was Director, Office of Regulatory Affairs, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases. There,…
2020-11-12 11:40:25
Nov. 12, 2020 – A video recording of the recent webinar on remote monitoring of pediatric clinical trials during the COVID-19 pandemic – co-sponsored by I-ACT for Children and Aparito – is now available at the following link: https://youtu.be/h-2DXjgXvTY. The Oct. 16 webinar – “Remote Patient Monitoring and Children in the COVID-19 Pandemic: What’s the Opportunity and…
2020-09-04 10:16:06
Sept. 1, 2020 – The FDA’s inclusion of children in its Emergency Use Authorization for use of remdesivir in treating serious COVID-19 disease is an important milestone, as it provides children with access to the medication at the same level of urgency afforded adults, according to an I-ACT for Children commentary published this week in…
2020-08-06 10:27:08
Collin Hovinga, PharmD, has been named to a four-year term as a member of the U.S. Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee. Dr. Hovinga, SVP of Clinical and Scientific Development at I-ACT for Children, joined the organization in 2018 and plays a lead role on many of our proprietary and…
2020-05-28 00:00:00
I-ACT for Children held a virtual workshop – “Developing Pediatric Treatments for COVID-19” – to discuss the progress of (and challenges related to) developing pediatric COVID-19 treatments with regulators, biopharma developers and experts on the front lines of treating children with COVID-19. Speakers shared the latest on the clinical presentation of COVID-19 in children, the…
